Keyphrases
Chronic Myeloid Leukemia
100%
Meta-analysis
95%
Systematic Meta-analysis
89%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
86%
Acute Myeloid Leukemia
86%
Leukemia Patients
58%
Confidence Interval
57%
Overall Survival
56%
Tyrosine Kinase Inhibitor
53%
Relative Risk
42%
Multiple Myeloma
39%
Hematological Malignancies
39%
Rituximab
36%
Acute Leukemia
34%
Diffuse Large B-cell Lymphoma (DLBCL)
32%
Imatinib
32%
Oncology Patients
32%
Relapsed or Refractory
32%
Chemotherapy
30%
Meta-analysis of Randomized Controlled Trials
29%
Israel
28%
Patients with Hematological Malignancies
26%
Hazard Ratio
26%
Chronic Lymphocytic Leukemia
26%
Graft-versus-host Disease (GvHD)
25%
Venous Thromboembolism
25%
Leukemia
24%
Newly Diagnosed
23%
Adverse Events
23%
Lymphoma Patients
23%
Positron Emission Tomography-computed Tomography (PET-CT)
23%
Single-center Experience
22%
Interferon-α (IFN-α)
22%
Acute Promyelocytic Leukemia
22%
Progression-free Survival
21%
Thrombocytopenia
21%
Human Telomerase Reverse Transcriptase (hTERT)
21%
Anticoagulation
20%
Bone Marrow
20%
Infectious Complications
19%
Dasatinib
19%
Randomized Controlled Trial
19%
Retrospective Cohort Study
18%
All-trans Retinoic Acid
18%
Acute Lymphoblastic Leukemia
18%
Atrial Fibrillation
18%
All-cause Mortality
18%
Sialyltransferase
18%
Venetoclax
18%
Ponatinib
18%
Medicine and Dentistry
Disease
67%
Acute Myeloid Leukemia
64%
Meta-Analysis
61%
Chronic Myelogenous Leukemia
60%
Hematologic Malignancy
53%
Hematopoietic Stem Cell
53%
Cell Transplantation
51%
Systematic Review
51%
Overall Survival
48%
Multiple Myeloma
40%
Tyrosine-Kinase Inhibitor
34%
Infection
33%
Acute Leukemia
31%
Malignant Neoplasm
30%
Diffuse Large B-Cell Lymphoma
30%
Adverse Event
29%
Randomized Controlled Trial
27%
Positron Emission Tomography-Computed Tomography
27%
Venous Thromboembolism
24%
Platelet
23%
Transplantation
22%
Hodgkin's Lymphoma
22%
Retrospective Study
21%
Diagnosis
20%
Rituximab
19%
Anticoagulation
19%
Progression Free Survival
18%
Imatinib
18%
Acute Lymphoblastic Leukemia
18%
Thrombocytopenia
18%
Leukemia
17%
Acute Promyelocytic Leukemia
16%
Non-Hodgkin Lymphoma
16%
Graft Versus Host Reaction
16%
Myelodysplastic Syndrome
16%
Ponatinib
15%
Arm
15%
Dasatinib
15%
Oncology
14%
Venetoclax
14%
Telomerase Reverse Transcriptase
14%
Febrile Neutropenia
14%
Tretinoin
14%
Cancer
13%
Computer Assisted Tomography
13%
Atrial Fibrillation
13%
Salvage Therapy
13%
Hematology
12%
Neoplasm
12%
Nilotinib
12%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
70%
Chronic Myeloid Leukemia
63%
Disease
61%
Overall Survival
56%
Infection
54%
Protein Tyrosine Kinase Inhibitor
49%
Adverse Event
47%
Randomized Controlled Trial
47%
Hematologic Malignancy
45%
Remission
44%
Chemotherapy
43%
Multiple Myeloma
40%
Malignant Neoplasm
40%
Rituximab
38%
Imatinib
34%
Chronic Lymphatic Leukemia
31%
Leukemia
22%
Cohort Study
21%
Acute Leukemia
20%
Telomerase
19%
Venous Thromboembolism
19%
Diffuse Large B Cell Lymphoma
18%
Neutropenia
18%
Nonhodgkin Lymphoma
18%
Venetoclax
18%
Graft Versus Host Reaction
18%
All Cause Mortality
17%
Infectious Complication
15%
Progression Free Survival
15%
Thrombocytopenia
15%
Immunoglobulin
15%
Direct Oral Anticoagulant
15%
Atrial Fibrillation
15%
Cytarabine
15%
Retinoic Acid
15%
Methotrexate
14%
Promyelocytic Leukemia
14%
Aplastic Anemia
14%
Sialyltransferase
14%
Myelofibrosis
14%
Ruxolitinib
14%
Observational Study
14%
Retrospective Study
13%
Ponatinib
13%
Febrile Neutropenia
13%
Telomerase Reverse Transcriptase
12%
Azacitidine
11%
Arterial Thromboembolism
11%
Neoplasm
11%
Bendamustine
11%